Osteoporosis
From the Journals
TNF inhibitors improve BMD in ankylosing spondylitis
But the treatment did not improve vertebral fracture outcomes or radiographic progression.
From the Journals
Frailty, diabetes increase fragility fracture risk
Frailty status may aid in understanding the diabetes bone paradox and enhance the quality of assessment and care for diabetes.
News
FDA committee votes yes on romosozumab for osteoporosis
FDA and the sponsor propose postmarketing surveillance to track a questionable cardiovascular safety signal.
From the Journals
Spending on medical marketing increased by $12.2 billion over the last 2 decades
“Although marketing expanded over the 2 decades, regulatory oversight remained relatively limited,” according to the authors.
From the Journals
Denosumab effective against osteoporosis in TDT patients
Denosumab increased bone density, reduced pain, and decreased markers of bone remodeling in patients with transfusion-dependent thalassemia.
From the Journals
Low BMD and spinal syndesmophytes predict radiographic progression in axSpA
Low BMD and the presence of existing spinal syndesmophytes predict the formation of new spinal bony growths and radiographic progression in axial...
Conference Coverage
Long-term follow-up results of ongoing trials highlighted at ACR 2018
Researchers will share long-term trial results in managing meniscal tears in osteoarthritis, treating glucocorticoid-induced osteoporosis, and...
Conference Coverage
Bisphosphonate holiday may help to reduce atypical femur fracture risk
Higher pretreatment bone mineral density appears to increase AFF risk as well.
Guidelines
New secondary fracture–prevention recommendations carry simple messages
Taking interventional action and communication between patients as well as other providers are integral elements of the recommendations.
Conference Coverage
Secondary fractures in older men spike soon after first, but exercise may help
Conference Coverage
Zoledronate reduces fracture risk in elderly women with osteopenia
Women with osteopenia who received intravenous zoledronate had a significantly lower risk of fractures.